Prognostic implications of imaging in atrophic macular degeneration and its use in clinical practice and clinical trial design

2016 ◽  
Vol 44 (5) ◽  
pp. 410-421 ◽  
Author(s):  
Paul CC Lim ◽  
Christopher J Layton
Keyword(s):  
Clinical Trial ◽  
Clinical Practice ◽  
Macular Degeneration ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Prognostic Implications

M1319 Do IBS Patients Understand the Difference Between Abdominal Pain vs. Discomfort? Implications for Clinical Practice and Clinical Trial Design

2010 ◽  
Vol 138 (5) ◽  
pp. S-379
Author(s):  
Brennan M. Spiegel ◽  
Roger E. Bolus ◽  
Lucinda A. Harris ◽  
Susan L. Lucak ◽  
Eric Esrailian ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Abdominal Pain ◽  
Clinical Practice ◽  
Trial Design ◽  
Clinical Trial Design ◽  
The Difference

scholarly journals Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars

2021 ◽  
Author(s):  
Luis Pérez Díaz ◽  
Susana Millán ◽  
Nuran Chaban ◽  
Ana del Campo ◽  
Eduardo Spitzer
Keyword(s):  
Clinical Trial ◽  
Monoclonal Antibodies ◽  
Clinical Practice ◽  
Clinical Management ◽  
Trial Design ◽  
Clinical Trial Design ◽  
Clinical Development ◽  
Point Selection ◽  
Substantial Impact ◽  
Current State

Monoclonal antibodies are highly complex, large and biologic products with a substantial impact on the clinical management of a variety of diseases including cancer. The expiry of patents for essential monoclonal antibodies in cancer care such as bevacizumab, rituximab and trastuzumab, has prompted the global development of biosimilars to balance the biologics market. However, an understanding of the different approach of biosimilar development compared with its reference medicinal product, especially in the context of clinical trial design and end point selection may help oncologists integrating biosimilars into clinical practice. Herein, we reviewed the clinical development of biosimilars in oncology comparing the available clinical data of proposed biosimilars of bevacizumab, rituximab and trastuzumab.

Integrating radiomics into clinical trial design

2019 ◽  
Vol 63 (4) ◽  
Author(s):  
Jessica J. Waninger ◽  
Michael D. Green ◽  
Catherine Cheze Le Rest ◽  
Benjamin Rosen ◽  
Issam El Naqa
Keyword(s):  
Clinical Trial ◽  
Trial Design ◽  
Clinical Trial Design
Sign in / Sign up

Export Citation Format

Share Document